BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 32.63 P/S
- 103.45 P/B
- -0.672 EPS
- -156.52% Cash ROIC
- 1.59 Cash Ratio
- 0 / 0% Dividend
- 1.04M Avg. Vol.
- 45.14M Shares
- 338.6M Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
Seeking Alpha - 11 hours ago
Seeking Alpha - 6 hours ago
Seeking Alpha - Dec 5, 2013
SBWire (press release) - Nov 30, 2013
SBWire (press release) - Nov 13, 2013
BioCryst Pharmaceuticals Upgraded by Merrill Lynch to "Neutral" (BCRX) - Zolmax
SBWire (press release) - Dec 9, 2013
Stocks Highlights: Amgen, Inc.(NASDAQ:AMGN), PDL BioPharma Inc. (NASDAQ ... - Market News Call
NIS - Dec 4, 2013
Techsonian (press release) - Dec 9, 2013
Market News Call - Dec 2, 2013
Small Cap Stocks in the Bullish Zone - Nuverra Environmental Solutions Inc ... - SBWire (press release)
PR Newswire (press release) - Nov 13, 2013